查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1866915

胶质瘤治疗市场按治疗方法、产品类型、胶质母细胞瘤分级、治疗线、分子亚型、患者年龄和最终用户划分－2025-2032年全球预测

Glioma Treatment Market by Treatment Modality, Product Type, Glioma Grade, Line Of Therapy, Molecular Subtype, Patient Age, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，胶质瘤治疗市场将成长至 96 亿美元，复合年增长率为 7.72%。

主要市场统计数据
基准年 2024 52.9亿美元
预计年份：2025年 57亿美元
预测年份：2032年 96亿美元
复合年增长率 (%) 7.72%

本书以严谨现代的方式介绍了胶质瘤治疗生态系统，重点在于分子精准性、多模态治疗整合和策略性临床要务。

胶质瘤是一组生物学特性多样的中枢神经系统肿瘤，持续给临床医生、研究人员和产业相关人员带来挑战。分子生物学的进步重塑了胶质瘤的分类和治疗，使研究重点从单纯依赖组织学转向整合分子分型以指南预后和治疗方案的选择。因此，临床决策越来越依赖生物标记，例如IDH突变状态和MGMT启动子甲基化，以对患者进行分层并制定个别化治疗方案。这加速了标靶药物和复杂生技药品的研发，同时也促使临床试验设计转向小规模、富含生物标记的队列。

重塑胶质母细胞瘤治疗的关键变革趋势包括分子诊断、免疫肿瘤学以及与价值和可及性相符的商业策略的进步。

在创新诊断、新一代疗法和适应性监管模式的推动下，胶质瘤的治疗格局正在经历一场变革。精准肿瘤学已从概念走向实践，IDH突变和MGMT启动子甲基化等分子分型已成为诊断流程的标准组成部分。这项转变不仅优化了预后分层，还促进了标靶治疗策略和生物标记主导的临床试验设计，从而优先考虑患者选择和讯号检测。

评估2025年美国关税调整对胶质母细胞瘤治疗供应链、采购韧性及临床项目连续性的累积影响

2025年，美国关税措施及相关贸易趋势的累积变化，已显着增加了胶质母细胞瘤治疗用药品和医疗设备供应链的复杂性。部分进口医疗用品和试剂关税的提高，以及影响生技药品进口的监管调整，凸显了供应链韧性的重要性。对于製造商和供应商而言，直接影响包括重新评估筹资策略、重新谈判供应商合同，以及加快探索区域性生产和经销伙伴关係，以降低成本波动和交货延迟的风险。

全面深入了解治疗方法、产品类型、分子亚型、患者人口统计特征、临床环境和治疗顺序之间的关係

深入的市场区隔对于理解胶质瘤治疗创新将在哪些领域产生最大的临床和商业性影响至关重要。在以治疗方法划分市场格局时，必须认识到化疗、免疫疗法、放射线治疗、手术和标靶治疗各自独立又相互依存的作用。化疗在许多治疗方案中仍然发挥着核心作用，在这一领域，烷化剂和抗微管药物的剂量优化以及联合用药策略仍在不断探索。免疫疗法正迅速发展，包括基因修饰疗法（如CAR-T细胞疗法）、全身性疗法（如查核点抑制剂）以及针对肿瘤特异性抗原的治疗性疫苗。放射线治疗的细分，包括近距离放射和体外放射疗法，突显了在最大限度发挥与全身疗法的协同作用的同时，最大限度地减少对周围组织影响的机会。针对EGFR和VEGF通道的分子标靶治疗是精准医疗方法抑制致癌性讯号传导和肿瘤血管生成的绝佳范例。

从区域实际观点探讨美洲、欧洲、中东和非洲以及亚太地区的研究实施、监管复杂性和准入策略。

区域趋势是影响胶质母细胞瘤治疗研究优先顺序、临床应用和商业策略的关键因素。在美洲，成熟的临床实验室网络、完善的医保报销管道和重点创新丛集促进了新型治疗方法的快速应用，而支付方的严格审查则要求提供临床和经济价值的有力证据。这种环境促使製定全面的证据生成计划和真实世界结果收集方案，以支持医保报销谈判和药物目录定位。

透过诊断整合和供应链韧性，策略性企业行动和伙伴关係模式推动胶质母细胞瘤治疗领域的差异化发展

在胶质母细胞瘤治疗生态系统中运作的公司正在拓展其产品组合，涵盖生物製剂、小分子药物、细胞疗法和诊断等领域，同时积极寻求将分子层面的洞见与治疗创新相结合的伙伴关係。成熟的製药和生物技术公司正利用其深厚的临床和监管经验，推进后期研发项目并扩大商业性运营，尤其是在高级别胶质母细胞瘤和针对主要分子亚型的药物方面。同时，新兴的生物技术和学术机构则专注于First-in-Class的作用机制、精准靶向分子和平台技术，这些技术与伴随诊断相结合，能够实现更个人化的治疗。

为产业领导者提供切实可行的高影响力建议，以协调分子开发、供应链韧性和证据产生与市场进入需求。

为了将科学进步转化为持续的临床和商业性成果，产业领导者应采取一系列切实可行的策略，使研发重点与营运实际情况和支付方的期望保持一致。首先，优先考虑以生物标记主导的研发计划，并儘早整合伴随诊断策略，可确保获得清晰的临床实验合格、明确的监管指导和医疗保险报销。这有助于降低研发风险，并透过锁定最有可能获益的患者群体，明确临床价值提案。

采用稳健的混合方法调查方法，结合专家访谈、文献综述、法规审查和严格的细分，以确保获得可操作的洞见。

本分析的调查方法结合了多种资讯来源和方法论，以确保其严谨性、相关性和可重复性。主要定性研究包括对临床医生、医疗系统采购人员、监管专家和行业高管进行结构化访谈，以识别决策驱动因素和营运限制因素。此外，也透过对同侪审查的临床文献、监管指导文件和公共临床试验註册库进行系统性回顾，为治疗和诊断趋势提供实证依据。

将胶质瘤治疗创新转化为可衡量的患者获益，需要整合临床、营运和商业性的要求。

总之，胶质母细胞瘤的治疗格局正处于一个转折点，分子标靶疗法、联合治疗和务实的商业策略的交汇融合，为意义深远的临床进展创造了机会。生物标记主导的方法正在重塑临床试验设计和治疗标靶，而免疫疗法、标靶药物和先进放射线治疗的创新则拓展了治疗选择。供应链的韧性、区域监管差异以及支付方的证据要求等实际因素，也将决定科学进步能否转化为广泛的临床效益。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 电磁场技术作为化疗和放射线治疗的辅助性治疗，在肿瘤治疗中迅速应用
  • 增加对復发性胶质母细胞瘤患者个人化新抗原疫苗研究的投入
  • 用于标靶药物递送的血脑障壁渗透性奈米颗粒取得突破性进展
  • 随着数位病理学和人工智慧成像平台的出现，优化胶质母细胞瘤的诊断和分级准确性
  • 提高术中磁振造影系统的核准，以提高胶质母细胞瘤切除手术的准确性
  • 扩大临床试验范围，探索新型IDH抑制剂治疗低度胶质瘤
  • 生技公司与学术机构的策略合作加速了胶质母细胞瘤免疫疗法的研发进程。

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 胶质瘤治疗市场：依治疗方法划分

  • 化疗
    • 烷化剂
    • 抗微管剂
  • 免疫疗法
    • CAR-T细胞疗法
    • 查核点抑制剂
    • 疫苗
  • 放射线治疗
    • 近距离放射
    • 体外放射线治疗
  • 外科手术
  • 标靶治疗
    • EGFR抑制剂
    • VEGF抑制剂

9. 依产品类型分類的胶质瘤治疗市场

  • 品牌产品
    • 生技药品
    • 低分子化合物
  • 学名药
    • 生技药品
    • 低分子化合物

第十章 胶质瘤治疗市场（依胶质母细胞瘤分级划分）

  • 优质
    • 间变性星状细胞瘤
    • 多形性胶质母细胞瘤
  • 低等级
    • 瀰漫性星状细胞瘤
    • 少突星状细胞瘤
    • 少突胶质细胞

第十一章 依治疗线分類的胶质瘤治疗市场

  • 主要治疗
  • 二级治疗
  • 三级治疗

第十二章 依分子亚型分類的胶质瘤治疗市场

  • Idh突变体
  • Idh野生型
  • Mgmt甲基化阳性
  • 未甲基化的 Mgmt

第十三章 依病患年龄组别分類的胶质瘤治疗市场

  • 成人
    • 18至64岁
    • 65岁或以上
  • 儿童
    • 13-17岁的青少年
    • 0-12岁儿童

第十四章 依最终用户分類的胶质瘤治疗市场

  • 门诊手术中心
  • 癌症研究所
  • 诊所
  • 医院

第十五章 各地区胶质瘤治疗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十六章 胶质瘤治疗市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十七章 各国胶质瘤治疗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十八章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • F. Hoffmann-La Roche AG
    • Merck & Co., Inc.
    • Novocure Ltd.
    • Bristol-Myers Squibb Company
    • Eisai Co., Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Dr. Reddy's Laboratories Ltd.
    • Pfizer Inc.
    • Novartis AG
    • Johnson & Johnson
Product Code: MRR-CD5A9334CE36

The Glioma Treatment Market is projected to grow by USD 9.60 billion at a CAGR of 7.72% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 5.29 billion
Estimated Year [2025] USD 5.70 billion
Forecast Year [2032] USD 9.60 billion
CAGR (%) 7.72%

A rigorous and contemporary introduction to the glioma treatment ecosystem emphasizing molecular precision, multi-modal care integration, and strategic clinical imperatives

Gliomas represent a biologically diverse class of central nervous system tumors that continue to challenge clinicians, researchers, and industry stakeholders. Advances in molecular biology have reframed how gliomas are classified and treated, shifting attention from histology alone to integrated molecular subtyping that informs prognosis and therapeutic selection. As a result, clinical decision making increasingly relies on biomarkers such as IDH mutation status and MGMT promoter methylation to stratify patients and to design personalized treatment regimens. This has accelerated development of targeted agents and complex biologics while also reshaping clinical trial design toward smaller, biomarker-enriched cohorts.

Concurrently, the treatment landscape is evolving across multiple modalities. Improvements in surgical technique, refinements in radiation delivery, enhancements in cytotoxic regimens, and the emergence of novel immuno-oncology approaches are converging to expand the clinician's toolkit. For industry leaders and clinical teams, the core challenge is integrating these modalities into cohesive treatment pathways that balance efficacy with tolerability and quality of life. With clinical trials exploring combinations of immunotherapies, targeted agents, and optimized radiochemotherapy sequences, the field is moving toward multi-modal regimens that are driven by molecular context and patient-specific factors.

From a commercial perspective, the market will be shaped by the interplay between scientific innovation, regulatory pathways, and health system readiness to adopt complex, often high-cost interventions. Payers and providers are increasingly focused on value-based approaches and real-world evidence to justify adoption. Therefore, developers and investors must align clinical development strategies with pragmatic endpoints and evidence generation plans that demonstrate meaningful clinical benefit for defined patient subgroups. In short, the current moment in glioma treatment is defined by a convergence of molecular insight and therapeutic innovation, which together create both opportunity and responsibility for stakeholders to deliver clinically meaningful advances.

Key transformative dynamics reshaping glioma care including molecular diagnostics, immuno-oncology advances, and commercial strategies aligned with value and access

The glioma treatment landscape is undergoing transformative shifts driven by technology-enabled diagnostics, next-generation therapeutics, and adaptive regulatory paradigms. Precision oncology has moved from concept to practice as molecular classifications such as IDH mutation and MGMT promoter methylation become standard components of diagnostic workups. This transition has not only refined prognostic stratification but has also unlocked targeted therapeutic strategies and biomarker-driven trial designs that prioritize patient selection and signal detection.

At the therapeutic front, immunotherapy approaches-ranging from checkpoint inhibition to engineered cell therapies and therapeutic vaccines-have gained prominence, even as they face the biological hurdles of the central nervous system microenvironment. Parallel advances in targeted small molecules and biologics, particularly agents aimed at growth factor pathways and specific oncogenic drivers, are expanding the armamentarium. Radiotherapy delivery has become more precise with image-guided techniques and hypofractionated regimens, which enable tighter integration with systemic therapies. Surgical innovation, supported by intraoperative imaging and molecular-guided resection strategies, continues to improve resection quality and postoperative outcomes.

Commercially, disruption is manifest in supply chain reconfiguration, strategic partnerships between biopharma and diagnostics firms, and a renewed emphasis on post-approval evidence generation. Payers are pushing for clear value narratives supported by patient-reported outcomes and real-world effectiveness data, prompting manufacturers to build robust evidence plans that extend beyond randomized controlled trials. Taken together, these shifts are redefining how new products are developed, trialed, and adopted in clinical practice, and they underscore the imperative for stakeholders to adopt integrated strategies that bridge science, regulation, and market access.

Assessing the cumulative consequences of 2025 United States tariff adjustments on glioma therapeutic supply chains, procurement resilience, and clinical program continuity

In 2025, cumulative changes in United States tariff policies and associated trade dynamics have introduced measurable complexity into pharmaceutical and medical device supply chains that support glioma care. Increased tariffs on certain imported medical goods and reagents, together with regulatory adjustments impacting biologic imports, have elevated the importance of supply chain resilience. For manufacturers and providers, the immediate ramifications include a reassessment of sourcing strategies, renegotiation of supplier contracts, and accelerated consideration of regional manufacturing or distribution partnerships to mitigate cost volatility and delivery delays.

The tariff environment has also influenced procurement decisions within health systems. Hospitals and networks that procure high-cost therapies, surgical implants, and precision diagnostics may face margin pressure as acquisition costs fluctuate. Consequently, procurement teams are prioritizing suppliers with robust contingency planning and transparent cost drivers. From a product development standpoint, companies are re-evaluating the global footprint of clinical trial materials, laboratory reagents, and device components to ensure continuity for ongoing studies and to protect timelines for pivotal programs. These operational responses are complemented by strategic shifts: firms are pursuing local fill-and-finish capabilities for biologics, diversifying vendor bases for critical raw materials, and leveraging contractual hedging mechanisms where feasible.

Importantly, tariffs have indirect effects on innovation pathways as well. Increased transaction costs and logistical friction can lengthen time-to-market and heighten the premium on efficient regulatory approval pathways. In response, developers are prioritizing early regulatory engagement and accelerated development strategies that use real-world evidence and adaptive trial designs. Importantly, while tariffs add a layer of cost and complexity, they have also catalyzed closer collaboration across the value chain and reinforced the business case for geographically diversified supply and manufacturing architectures that bolster long-term program resilience.

Comprehensive segmentation-driven insights linking therapeutic modality, product type, molecular subtype, patient demographics, care setting, and treatment sequencing

Insightful segmentation is foundational to understanding where innovation will have the greatest clinical and commercial impact in glioma care. When market perspectives are organized by treatment modality, it is essential to recognize the distinct but interdependent roles of chemotherapy, immunotherapy, radiotherapy, surgery, and targeted therapy. Chemotherapy remains a backbone in many regimens and, within that domain, alkylating agents and anti-microtubule agents continue to be optimized for dosing and combination strategies. Immunotherapy is rapidly diversifying into engineered approaches such as CAR T-cell therapies, systemic approaches such as checkpoint inhibitors, and therapeutic vaccines aimed at tumor-specific antigens. Radiotherapy subdivisions including brachytherapy and external beam approaches provide opportunities to synergize with systemic agents while minimizing collateral tissue effects. Targeted therapy efforts focused on EGFR and VEGF pathways exemplify the precision approach to inhibit oncogenic signaling and tumor angiogenesis.

Product type segmentation clarifies how innovation pipelines and access dynamics differ between branded and generic offerings, with both categories encompassing biologics and small molecule classes. Branded biologics and small molecules command differentiated development and regulatory considerations, while generics-whether biologic or small molecule-play a crucial role in expanding access and in forming competitive backdrops that influence pricing and uptake. Understanding glioma grade stratification is equally important: high-grade tumors, including anaplastic astrocytoma and glioblastoma multiforme, demand aggressive multimodal approaches and are the focus of many advanced therapeutic trials, whereas low-grade entities such as diffuse astrocytoma, oligoastrocytoma, and oligodendroglioma are managed with approaches that balance long-term disease control and functional preservation.

Line-of-therapy segmentation-first line through third line-frames where novel agents may be deployed and how clinical outcomes benchmarks differ across treatment sequences. Molecular subtype segmentation highlights the centrality of IDH mutation status, IDH wildtype designation, and MGMT promoter methylation status in shaping therapeutic choices and trial eligibility. Patient age cohorts differentiate adult and pediatric populations, with adults further stratified into 18-64 and 65+ brackets and pediatric categories split into adolescents (13-17) and children (0-12); age-related considerations influence dosing, safety profiles, and trial design. Finally, end user segmentation across ambulatory surgical centers, cancer research institutes, clinics, and hospitals illuminates varied adoption pathways and organizational capabilities for implementing advanced treatments and diagnostics. Together, this multi-dimensional segmentation framework supports targeted clinical strategies and tailored commercialization plans that align product profiles with the most receptive clinical niches.

Actionable regional perspectives on research adoption, regulatory complexity, and access strategies across the Americas, Europe Middle East & Africa, and Asia-Pacific

Regional dynamics are a decisive force shaping research prioritization, clinical adoption, and commercial strategy for glioma therapeutics. In the Americas, mature clinical trial networks, established reimbursement pathways, and concentrated innovation clusters foster rapid adoption of novel modalities, while also presenting payer scrutiny that demands robust evidence of clinical and economic value. This environment incentivizes comprehensive evidence-generation plans and real-world outcomes collection to support reimbursement discussions and formulary positioning.

Europe, the Middle East & Africa present a heterogeneous landscape where regulatory harmonization across some European markets coexists with variable access and infrastructure in other territories. Centralized regulatory processes and strong academic centres in portions of Europe facilitate pan-regional trial designs, but divergent national health technology assessment processes require localized value narratives and adaptive pricing strategies. Across the Middle East and Africa, growing investment in oncology infrastructure is expanding clinical trial participation and access to advanced therapeutics, yet disparities in diagnostic capacity and treatment availability remain important considerations for commercial engagement.

The Asia-Pacific region offers rapid innovation uptake in select markets that combine strong clinical trial capacity with growing domestic biopharma capabilities. Regulatory authorities in several Asia-Pacific countries are introducing pathways that accelerate approvals for therapies addressing high unmet need, which can support earlier commercialization and regional launches. However, heterogeneous payer landscapes and variable biomarker testing infrastructure mean that companies must calibrate launch sequencing, local partnerships, and capacity-building investments to ensure sustained uptake and optimized patient access. Across all regions, coordinated engagement with local key opinion leaders, investment in diagnostic capacity, and adaptive market access strategies are vital to translate scientific advances into widespread clinical benefit.

Strategic company behaviors and partnership models driving differentiation in glioma therapeutics through diagnostics integration and supply chain resilience

Companies operating in the glioma treatment ecosystem are diversifying their portfolios across biologics, small molecules, cell therapies, and diagnostics while pursuing partnerships that couple molecular insights with therapeutic innovation. Established pharmaceutical and biotechnology firms are leveraging deep clinical and regulatory experience to advance late-stage programs and to scale commercial operations, particularly for agents addressing high-grade gliomas and key molecular subtypes. At the same time, emerging biotechs and academic spinouts are concentrating on first-in-class mechanisms, precision-targeted molecules, and platform technologies that can be combined with companion diagnostics to deliver more personalized care.

Strategic behaviors observed across the competitive landscape include alliance formation between therapeutic developers and diagnostic companies to secure companion testing pathways, licensing arrangements that accelerate access to regional expertise, and selective in-licensing to broaden pipelines without overextending internal R&D capacity. Additionally, some companies are making targeted investments in manufacturing and supply chain capabilities-especially for complex biologics and cell therapies-to reduce exposure to trade-related disruptions and to improve time-to-patient. Commercially, organizations are refining launch playbooks by integrating payer engagement earlier in development and by designing evidence generation plans that emphasize patient-centered outcomes and comparative effectiveness. Overall, the competitive environment rewards nimble operators that can integrate molecular diagnostics, demonstrate real-world value, and form pragmatic partnerships that de-risk development and accelerate adoption.

High-impact, actionable recommendations for industry leaders to align molecular development, supply chain resilience, and evidence generation with market access needs

To convert scientific advances into durable clinical and commercial outcomes, industry leaders should adopt a set of pragmatic, executable strategies that align development priorities with operational realities and payer expectations. First, prioritize biomarker-driven development plans that integrate companion diagnostic strategies from the outset, ensuring trial eligibility, regulatory clarity, and a clear pathway to reimbursement. This reduces development risk and sharpens the clinical value proposition by targeting the patients most likely to benefit.

Second, proactively address supply chain and manufacturing vulnerabilities by diversifying suppliers, investing in regional fill-and-finish capabilities for biologics, and establishing contingency plans for critical raw materials. These steps protect timelines for clinical programs and reduce exposure to tariff-driven volatility. Third, design evidence generation programs that extend beyond traditional randomized controlled trials to include well-structured real-world evidence and patient-reported outcome measures; these data streams are increasingly vital in payer discussions and in demonstrating comparative effectiveness in routine practice. Fourth, pursue collaborative commercial models with diagnostics firms, academic centers, and health systems to build integrated care pathways that support uptake at the point of care. Finally, adopt adaptive pricing and access strategies that reflect regional payer environments and that enable tiered approaches to reimbursement, such as outcomes-based agreements or access programs that bridge early adoption to broader coverage. By implementing these measures, companies can accelerate clinical adoption, enhance payer confidence, and reduce operational risk across the product lifecycle.

A robust mixed-methods research methodology integrating expert interviews, literature synthesis, regulatory review, and rigorous segmentation to ensure actionable insights

The research methodology underpinning this analysis combined multiple sources and methodological approaches to ensure rigor, relevance, and reproducibility. Primary qualitative research included structured interviews with clinicians, health system procurement leaders, regulatory experts, and industry executives to surface decision drivers and operational constraints. These insights were complemented by systematic reviews of peer-reviewed clinical literature, regulatory guidance documents, and publicly available clinical trial registries to ground therapeutic and diagnostic trends in empirical evidence.

Data triangulation was applied to reconcile findings across sources and to identify consistent themes related to biomarker adoption, modality integration, and access challenges. The segmentation approach organized insights across treatment modality, product type, glioma grade, line of therapy, molecular subtype, patient age, and end-user type, enabling focused analysis of clinical and commercial implications for each stratum. Quality assurance processes included expert validation panels and cross-checking of clinical facts against primary literature. Limitations of the research are acknowledged, including the evolving nature of clinical evidence and regional heterogeneity in diagnostic capacity, which may affect the timing and magnitude of adoption. Nonetheless, the applied methodology delivers a robust foundation for strategic decision-making by integrating clinician perspectives, regulatory context, and commercial considerations.

Concluding synthesis of clinical, operational, and commercial imperatives that must align to translate glioma innovation into measurable patient benefit

In conclusion, the glioma treatment landscape is at an inflection point where molecular precision, multi-modality therapeutics, and pragmatic commercial strategies intersect to create opportunity for meaningful clinical progress. Biomarker-driven approaches are reshaping trial design and therapeutic targeting, while innovations in immunotherapy, targeted agents, and advanced radiotherapy are expanding therapeutic options. Operational realities such as supply chain resilience, regional regulatory differences, and payer evidence requirements are equally determinative in whether scientific advances translate into widespread clinical benefit.

Stakeholders that align development programs with diagnostic strategies, invest in resilient manufacturing and distribution models, and generate evidence that resonates with payers and clinicians will be best positioned to accelerate adoption. The path forward requires coordinated actions across the value chain: developers must deliver differentiated clinical benefit in clearly defined patient subgroups; diagnostic partners must ensure access to high-quality molecular testing; and health systems must prepare clinical pathways that enable timely and equitable access. By synthesizing scientific rigor with operational discipline and stakeholder collaboration, the community can enhance outcomes for patients living with glioma and deliver sustainable innovation to clinical practice.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rapid adoption of tumor treating fields technology as an adjunct to chemotherapy and radiotherapy
  • 5.2. Increasing investment in personalized neoantigen vaccine research for recurrent glioblastoma patients
  • 5.3. Breakthrough development of blood-brain barrier penetrating nanoparticles for targeted drug delivery
  • 5.4. Emergence of digital pathology and AI-powered imaging platforms optimizing glioma diagnosis and grading accuracy
  • 5.5. Rising approvals of intraoperative MRI systems to enhance surgical precision in glioma resections
  • 5.6. Expansion of clinical trials exploring novel IDH inhibitors for treatment of low grade gliomas
  • 5.7. Strategic partnerships between biotech firms and academic centers accelerating glioma immunotherapy pipelines

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Glioma Treatment Market, by Treatment Modality

  • 8.1. Chemotherapy
    • 8.1.1. Alkylating Agents
    • 8.1.2. Anti-Microtubule Agents
  • 8.2. Immunotherapy
    • 8.2.1. Car T-Cell Therapy
    • 8.2.2. Checkpoint Inhibitors
    • 8.2.3. Vaccines
  • 8.3. Radiotherapy
    • 8.3.1. Brachytherapy
    • 8.3.2. External Beam Radiotherapy
  • 8.4. Surgery
  • 8.5. Targeted Therapy
    • 8.5.1. Egfr Inhibitors
    • 8.5.2. Vegf Inhibitors

9. Glioma Treatment Market, by Product Type

  • 9.1. Branded
    • 9.1.1. Biologics
    • 9.1.2. Small Molecule
  • 9.2. Generic
    • 9.2.1. Biologics
    • 9.2.2. Small Molecule

10. Glioma Treatment Market, by Glioma Grade

  • 10.1. High Grade
    • 10.1.1. Anaplastic Astrocytoma
    • 10.1.2. Glioblastoma Multiforme
  • 10.2. Low Grade
    • 10.2.1. Diffuse Astrocytoma
    • 10.2.2. Oligoastrocytoma
    • 10.2.3. Oligodendroglioma

11. Glioma Treatment Market, by Line Of Therapy

  • 11.1. First Line
  • 11.2. Second Line
  • 11.3. Third Line

12. Glioma Treatment Market, by Molecular Subtype

  • 12.1. Idh Mutant
  • 12.2. Idh Wildtype
  • 12.3. Mgmt Methylation Positive
  • 12.4. Mgmt Unmethylated

13. Glioma Treatment Market, by Patient Age

  • 13.1. Adult
    • 13.1.1. 18-64
    • 13.1.2. 65+
  • 13.2. Pediatric
    • 13.2.1. Adolescents 13-17
    • 13.2.2. Children 0-12

14. Glioma Treatment Market, by End User

  • 14.1. Ambulatory Surgical Centers
  • 14.2. Cancer Research Institutes
  • 14.3. Clinics
  • 14.4. Hospitals

15. Glioma Treatment Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Glioma Treatment Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Glioma Treatment Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. Competitive Landscape

  • 18.1. Market Share Analysis, 2024
  • 18.2. FPNV Positioning Matrix, 2024
  • 18.3. Competitive Analysis
    • 18.3.1. F. Hoffmann-La Roche AG
    • 18.3.2. Merck & Co., Inc.
    • 18.3.3. Novocure Ltd.
    • 18.3.4. Bristol-Myers Squibb Company
    • 18.3.5. Eisai Co., Ltd.
    • 18.3.6. Teva Pharmaceutical Industries Ltd.
    • 18.3.7. Dr. Reddy's Laboratories Ltd.
    • 18.3.8. Pfizer Inc.
    • 18.3.9. Novartis AG
    • 18.3.10. Johnson & Johnson

LIST OF FIGURES

  • FIGURE 1. GLOBAL GLIOMA TREATMENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY GLIOMA GRADE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY GLIOMA GRADE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY MOLECULAR SUBTYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY MOLECULAR SUBTYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. NORTH AMERICA GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. LATIN AMERICA GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA GLIOMA TREATMENT MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. EUROPE GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. MIDDLE EAST GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. AFRICA GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASEAN GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GCC GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. EUROPEAN UNION GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BRICS GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. G7 GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. NATO GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. GLIOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 34. GLIOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. GLIOMA TREATMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL GLIOMA TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL GLIOMA TREATMENT MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY ALKYLATING AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY ANTI-MICROTUBULE AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY ANTI-MICROTUBULE AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY ANTI-MICROTUBULE AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY ANTI-MICROTUBULE AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY ANTI-MICROTUBULE AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY ANTI-MICROTUBULE AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CAR T-CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CAR T-CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CAR T-CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CAR T-CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CHECKPOINT INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY BRACHYTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY EXTERNAL BEAM RADIOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY EGFR INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY EGFR INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY EGFR INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY EGFR INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY EGFR INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY VEGF INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY VEGF INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY VEGF INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY VEGF INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY VEGF INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY VEGF INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY BRANDED, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY BRANDED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY BRANDED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY BRANDED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY BRANDED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY BRANDED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY BRANDED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY BIOLOGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY GENERIC, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY GENERIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY GENERIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY GENERIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY GENERIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY GENERIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY GENERIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY BIOLOGICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY BIOLOGICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY BIOLOGICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY BIOLOGICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY SMALL MOLECULE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY SMALL MOLECULE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY GLIOMA GRADE, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY GLIOMA GRADE, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY HIGH GRADE, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY HIGH GRADE, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY HIGH GRADE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY HIGH GRADE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY HIGH GRADE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY HIGH GRADE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY HIGH GRADE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY HIGH GRADE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY ANAPLASTIC ASTROCYTOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY ANAPLASTIC ASTROCYTOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY ANAPLASTIC ASTROCYTOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY ANAPLASTIC ASTROCYTOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY ANAPLASTIC ASTROCYTOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY ANAPLASTIC ASTROCYTOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY GLIOBLASTOMA MULTIFORME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY GLIOBLASTOMA MULTIFORME, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY GLIOBLASTOMA MULTIFORME, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY GLIOBLASTOMA MULTIFORME, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY GLIOBLASTOMA MULTIFORME, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY GLIOBLASTOMA MULTIFORME, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY LOW GRADE, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY LOW GRADE, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY LOW GRADE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY LOW GRADE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY LOW GRADE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY LOW GRADE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY LOW GRADE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY LOW GRADE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY DIFFUSE ASTROCYTOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY DIFFUSE ASTROCYTOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY DIFFUSE ASTROCYTOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY DIFFUSE ASTROCYTOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY DIFFUSE ASTROCYTOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY DIFFUSE ASTROCYTOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY OLIGOASTROCYTOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY OLIGOASTROCYTOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY OLIGOASTROCYTOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY OLIGOASTROCYTOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY OLIGOASTROCYTOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY OLIGOASTROCYTOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY OLIGODENDROGLIOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY OLIGODENDROGLIOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY OLIGODENDROGLIOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY OLIGODENDROGLIOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY OLIGODENDROGLIOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY OLIGODENDROGLIOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY FIRST LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY SECOND LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY THIRD LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY THIRD LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY THIRD LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY THIRD LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY THIRD LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY MOLECULAR SUBTYPE, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY MOLECULAR SUBTYPE, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY IDH MUTANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY IDH MUTANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY IDH MUTANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY IDH MUTANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY IDH MUTANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY IDH MUTANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY IDH WILDTYPE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY IDH WILDTYPE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY IDH WILDTYPE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY IDH WILDTYPE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY IDH WILDTYPE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY IDH WILDTYPE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY MGMT METHYLATION POSITIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY MGMT METHYLATION POSITIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY MGMT METHYLATION POSITIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY MGMT METHYLATION POSITIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY MGMT METHYLATION POSITIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY MGMT METHYLATION POSITIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY MGMT UNMETHYLATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY MGMT UNMETHYLATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY MGMT UNMETHYLATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY MGMT UNMETHYLATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY MGMT UNMETHYLATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY MGMT UNMETHYLATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY PATIENT AGE, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY ADULT, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY ADULT, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY ADULT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY ADULT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY ADULT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY 18-64, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY 18-64, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY 18-64, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY 18-64, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY 18-64, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY 18-64, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY 65+, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY 65+, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY 65+, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY 65+, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY 65+, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY 65+, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY PEDIATRIC, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY PEDIATRIC, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY PEDIATRIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY ADOLESCENTS 13-17, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY ADOLESCENTS 13-17, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY ADOLESCENTS 13-17, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY ADOLESCENTS 13-17, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY ADOLESCENTS 13-17, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY ADOLESCENTS 13-17, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CHILDREN 0-12, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CHILDREN 0-12, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CHILDREN 0-12, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CHILDREN 0-12, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CHILDREN 0-12, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CHILDREN 0-12, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 285. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 286. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 287. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 288. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 289. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 290. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CANCER RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 291. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 292. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 293. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 294. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 295. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 298. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 301. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 304. GLOBAL GLIOMA TREATMENT MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 305. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 306. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 307. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2018-2024 (USD MILLION)
  • TABLE 308. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY TREATMENT MODALITY, 2025-2032 (USD MILLION)
  • TABLE 309. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 310. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 311. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 312. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 313. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 314. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY RADIOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 315. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2018-2024 (USD MILLION)
  • TABLE 316. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, 2025-2032 (USD MILLION)
  • TABLE 317. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 318. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 319. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY BRANDED, 2018-2024 (USD MILLION)
  • TABLE 320. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY BRANDED, 2025-2032 (USD MILLION)
  • TABLE 321. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY GENERIC, 2018-2024 (USD MILLION)
  • TABLE 322. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY GENERIC, 2025-2032 (USD MILLION)
  • TABLE 323. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY GLIOMA GRADE, 2018-2024 (USD MILLION)
  • TABLE 324. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY GLIOMA GRADE, 2025-2032 (USD MILLION)
  • TABLE 325. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY HIGH GRADE, 2018-2024 (USD MILLION)
  • TABLE 326. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY HIGH GRADE, 2025-2032 (USD MILLION)
  • TABLE 327. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY LOW GRADE, 2018-2024 (USD MILLION)
  • TABLE 328. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY LOW GRADE, 2025-2032 (USD MILLION)
  • TABLE 329. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
  • TABLE 330. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
  • TABLE 331. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY MOLECULAR SUBTYPE, 2018-2024 (USD MILLION)
  • TABLE 332. AMERICAS GLIOMA TREATMENT MARKET SIZE, BY MOLECULAR SUBTYPE, 2025-2032 (USD MILLION)
  • TABLE 333. AM